Research programme: neurological disorder therapeutics - NeuroRepair

Drug Profile

Research programme: neurological disorder therapeutics - NeuroRepair

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator NeuroRepair; University of California at Irvine
  • Class Antineoplastics; Antiulcers; Antivirals; Growth factors; Transforming growth factors
  • Mechanism of Action Transforming growth factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Parkinson's disease; Stroke

Most Recent Events

  • 28 Jul 2016 Preclinical trials in Parkinson's disease in USA (Parenteral)
  • 28 Jul 2016 Preclinical trials in Stroke in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top